| Cover | Oct. 20, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | On October 25, 2023, OptimizeRx filed with the Securities and Exchange Commission a Current Report on Form 8-K (the “Original Form 8-K”) to report the consummation of the Merger. Among other things, this Amendment No. 1 to the Original Form 8-K amends and supplements Item 9.01 of the Original Form 8-K to provide the financial statements and pro forma financial information required under Items 9.01(a) and (b) of Form 8-K, which were excluded from the Original Form 8-K in reliance on the instructions to such items. |
| Document Period End Date | Oct. 20, 2023 |
| Entity File Number | 001-38543 |
| Entity Registrant Name | OptimizeRx Corporation |
| Entity Central Index Key | 0001448431 |
| Entity Tax Identification Number | 26-1265381 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 260 Charles Street |
| Entity Address, Address Line Two | Suite 302 |
| Entity Address, City or Town | Waltham |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02453 |
| City Area Code | 248 |
| Local Phone Number | 651.6568 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.001 Par Value |
| Trading Symbol | OPRX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
